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Objective: This study investigated the occurrence of the p190 and p210 breakpoint cluster
region-Abelson (BCR-ABL) rearrangements in adults with acute lymphoblastic leukemia and
possible associations with clinical and laboratory characteristics and survival.
Methods: Forty-one over 18-year-old patients with acute lymphoblastic leukemia of both
genders followed-up between January 2008 and May 2012 were included in this study. Clinical
and  laboratory data were obtained from the medical charts of the patients. Reverse transcrip-
tion polymerase chain reaction (RT-PCR) using speciﬁc primers was employed to identify
molecular rearrangements.
Results: At diagnosis, the median age was 33 years, and there was a predominance of males
(61%). The most common immunophenotype was B lineage (76%). BCR-ABL rearrangements
was  detected in 14 (34%) patients with the following distribution: p190 (28%), p210 (50%) and
double positive (22%). Overall survival of patients with a mean/median of 331/246 days of
follow up was 39%, respectively, negative BCR-ABL (44%) and positive BCR-ABL (28%).
Conclusion: These results conﬁrm the high frequency of BCR-ABL rearrangements and the
low  survival rate of adult Brazilian patients with acute lymphoblastic leukemia.©  2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
survival of 35% in patients aged between 18 and 60 years. Asntroduction
cute lymphoblastic leukemia (ALL) in adults comprises a
roup of diseases with biological, clinical, laboratorial and
rognostic heterogeneity characterized by abnormal prolifera-
ion and accumulation of immature lymphoid cells in the bone
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marrow and lymphoid tissues.1 Unlike ALL in children, the
advances in the therapy in adults have been slow, with a mean
2o de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Rua
a result, considerable effort has been made to identify mark-
ers that can be translated to the clinic as new prognostic tools
and therapeutic targets.3
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Table 1 – Clinical features at diagnosis of 41 adult
patients with acute lymphoblastic leukemia from 2008
to 2012 at HEMOPE.
Clinical features
Age (Years) – n (%)
18–34 23 (56)
35–60 14 (34)
>60 4 (10)
Median (range) 33 (19–72)
Gender – n (%)
Male 25 (61)
Female 16 (39)
Leucocytes (×109/L)
Median (range) 47 (0.3–570.5)
Lymphoblasts PB (%)
Median (range) 78 (0–98)
Platelets (×109/L)
Median (range) 47 (8–571)
Hemoglobin (g/dL)
Median (range) 8.5 (2.7–12.9)
Immunophenotype – n (%)
B-ALL 31 (76)352  rev bras hematol hem
At present, the diagnosis and classiﬁcation of acute
leukemia depend on cytomorphologic, immunophenotypic,
cytogenetic and molecular analyses. Molecular tests are part
of the criteria for the risk classiﬁcation system of the World
Health Organization (WHO) and are used to evaluate the prog-
nosis correctly and deﬁne therapeutic strategies.4
Of the various genetic alterations observed in adult ALL,
the breakpoint cluster region-Abelson (BCR-ABL) fusion gene
is the most common and is associated with a particularly poor
prognosis.1,5,6 This gene rearrangement can present two dis-
tinct isoforms, p190 and p210 due to different breakpoints.7
Recent studies indicate that these two isoforms may be associ-
ated with different clinical phenotypes in adult ALL patients.8
The aim of this study was to investigate the occurrence
of the p190 and p210 BCR-ABL rearrangements in adult ALL
patients and to investigate possible associations with clinical
and laboratory features and survival.
Methods
The study group comprised 41 over 18-year-old patients
of both genders diagnosed with ALL at the Fundac¸ão de
Hematologia e Hemoterapia de Pernambuco (Hemope) from
January 2008 to May 2012. The diagnosis was established by
clinical, cytomorphological and immunophenotypic criteria.
The standard treatment protocol used was the hyperfrac-
tionated cyclophosphamide, vincristine, doxorubicin, and
dexamethasone (HyperCVAD) regimen.9 This project was
approved by the Research Ethics Committee of the institution
(#17/2010) and the study was conducted in accordance with
the Declaration of Helsinki 2008.
Clinical and laboratory data were obtained from the
patients’ records. Samples of peripheral blood and bone
marrow were collected after informed consent had been
given. The identiﬁcation of the p190 and p210 BCR-ABL gene
rearrangements was performed by reverse transcription poly-
merase chain reaction (RT-PCR) according to the international
BIOMED-1 protocol.10 The following controls were used in the
RT-PCR reactions: positive, negative, endogenous and contam-
ination.
Statistical analysis was performed using the Bioestat 5.0
and Stata 9.1 programs. The t-test was used to compare the
groups regarding age, leukocyte count, blasts, platelet count
and hemoglobin. The Fisher exact test was used for the
categorical variables (gender and immunophenotype). Over-
all survival was calculated using the Kaplan–Meier Log rank
method. p-values <0.05 were considered statistically signiﬁ-
cant.
Results
Of the 41 patients analyzed, ALL was more  prevalent in young
adults and men  and the most common immunophenotype
was B lineage (Table 1).
No statistically signiﬁcant differences were found between
the groups of BCR-ABL positive and negative patients in respect
to the clinical and laboratory variables. However, the p210 BCR-
ABL patients had higher leukocyte counts and all p190 BCR-ABL
patients had the B immunophenotype (Table 2).T-ALL 9 (22)
Not done 1 (2)
The overall survival was 39% with a mean follow-up of
331 days (median 246 days). Survival was lower for BCR-ABL
positive (28%) than for BCR-ABL negative (44%) patients. The
Log-rank test, however, showed no statistically signiﬁcant dif-
ference (p-value = 0.2297) between the survival curves of the
two groups (Fig. 1). The mortality rate of BCR-ABL positive
patients is 1.94 times greater [95% Conﬁdence Interval (CI):
0.80–4.26] than the BCR-ABL negative individuals, but again the
difference is not statistically signiﬁcant (p-value = 0.148).
Discussion
The median age of the patients was 33 years, which is sim-
ilar to several published series.11–17 Males predominated in
the sample, which is in accordance with the main multicen-
ter studies.11–15,18–21 The results of several studies have shown
similar numbers of leucocytes11,12,20 at diagnosis, including
the percentage of blasts in the peripheral blood13 and platelet
count.17 The 76% frequency of B cell phenotype is in accor-
dance with various published studies.11,12,17,21–23
The 34% frequency of the BCR-ABL rearrangement is similar
to that found in several studies with values ranging from 17%
to 37%,1,11–14,17–22 including in elderly patients, as reported by
Larson.24 No published Brazilian studies with data regarding
the molecular analysis of BCR-ABL in adult ALL patients were
found for comparison. A case series of 42 adult Brazilian
patients showed 7% of Ph+ samples.25
The results presented in this study conﬁrm the high fre-
quency of BCR-ABL rearrangements in adult ALL patients,
but, differ from other studies regarding the type of isoforms
found. Gleier et al.21 showed a 37% positivity for the BCR-
ABL fusion gene in 478 adult ALL patients including the p190
(77%) and p210 (20%) rearrangements and both isoforms (3%).
Dombret et al.22 found the following frequencies among 154
adult ALL patients: p190 (68%), p210 (28%) and both isoforms
(4%). The explanation for our results is not clear, including the
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Table 2 – Summary of clinical and laboratory parameters of 41 adult patients diagnosed with acute lymphoblastic
leukemia at HEMOPE.
Variable BCR-ABL−
(n = 27)
BCR-ABL+
(n = 14)
BCR-ABL+
p190
(n = 4)
BCR-ABL+
p210
(n = 7)
BCR-ABL+
p190/p210
(n = 3)
Age (years)
Median (range) 35 (19–72) 38 (20–72) 45 (22–61) 35 (20–72) 34 (20–48)
Leucocytes (×109/L)
Median (range) 30.4 (1–492) 77.1 (0.3–570) 76.6 (0.3–378) 96.0 (6.7–570) 7.7 (4.2–298.8)
Platelets (×109/L)
Median (range) 41 (8–571) 69 (18–213) 175.5 (18–213) 60 (27–155) 70 (60–112)
Lymphoblasts (%)
Median (range) 78 (0–97) 80 (0–98) 75 (0–93) 85 (31–98) 36 (3–94)
Immunophenotypea – n (%)
B-ALL 21 (78.0) 10 (71.5) 4 (100.0) 3 (43.0) 3 (100.0)
T-ALL 5 (22.0) 4 (28.5) 0 (0) 4 (57.0) 0 (0)
−: negative; +: positive.
a n = 40.
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Figure 1 – Overall survival curves of 41 adult patients with acute lymphoblastic leukemia at Fundac¸ão HEMOPE according to
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ccurrence of BCR-ABL positivity in T-ALL cases19, but may be
ue to sample size or characteristics of the population stud-
ed, as well as patients with chronic myeloid leukemia in acute
hase.26
The analysis of the survival curves, in addition to con-
rming the low rate of overall survival for adult patients
iagnosed with ALL,9,14,20,21,23 also suggests an increased
dverse prognosis conferred by the presence of BCR-ABL
earrangements,2,18,21–23,27 and therefore a need for other ther-
peutic modalities, including targeted therapies and bone
arrow transplantation.28 The range of the conﬁdence inter-al of the mortality rate suggests that the sample size was too
mall to show a difference and that increasing it would make it
ore  evident. Phenotypic differences between p190 and p210
CR-ABL patients is controversial.8,21 Further studies with alarger sample size, including elderly patients, are needed to
better characterize the association between these rearrange-
ments and different phenotypic expressions and survival. The
detection of the BCR-ABL fusion gene is important for the
classiﬁcation of risk groups of ALL patients and the correct
targeting of therapy.2,3 Moreover, in addition to the BCR-ABL
fusion gene, other rearrangements, such as E2A-PBX1,  TEL-
AML1, MLL-AF4, should be screened, because they also have
prognostic signiﬁcance.29Conclusion
Our results provide the ﬁrst published evidence of the high
frequency of BCR-ABL and poor survival in adult Brazilian ALL
oter.
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patients. The study conﬁrms the importance of detecting BCR-
ABL rearrangements for the treatment and prognosis of these
patients.
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